#None #Class Action #Kahn Swick & Foti #ADMA Biologics

Important Deadline for ADMA Biologics Class Action Lawsuit

A recent notice has been issued regarding a class action lawsuit against ADMA Biologics, Inc., giving investors a critical update on their rights and potential claims. The firm Kahn Swick & Foti, LLC (KSF), along with their partner and former Louisiana Attorney General, Charles C. Foti, Jr., is actively seeking to notify affected investors about the lawsuit's details. This case concerns investors who purchased stock between August 9, 2024, and March 25, 2026, inclusive.

Understanding the Class Action

The lawsuit aims to recover financial losses incurred by investors due to ADMA Biologics' alleged misrepresentation and omission of material information from their offering documents. Within the lawsuit, specific claims have been made against the company and some of its executives, highlighting that they failed to disclose significant information which may have affected the decisions of investors.

Key allegations include involvement in undisclosed related party transactions, artificial inflation of revenue through channel stuffing practices, and inadequate internal controls, all of which contributed to misleading statements regarding the company's operational integrity and growth prospects.

As the legal proceedings unfold, the lawsuit is currently pending in the United States District Court for the District of New Jersey under the case title Mazzarino v. ADMA Biologics, Inc., et al, No. 26-cv-04793.

What Investors Need to Know

Affected investors have until August 10, 2026 to apply to be lead plaintiffs in the case. Notably, while serving as lead plaintiff holds certain benefits, it is not a requirement to participate in any potential recovery from the case. This means that even if individuals do not wish to take on the lead role, they can still seek compensation for their losses.

Investors seeking more information or who are interested in participating in the lawsuit are encouraged to reach out to KSF's managing partner, Lewis Kahn, directly. He can be contacted toll-free at 1-877-515-1850 or via email at [email protected] Further details are also available on KSF's official website, which provides important resources and updates about the ongoing case and other related litigations.

About Kahn Swick & Foti, LLC

KSF has built a reputation as one of the nation's top boutique securities litigation law firms, known for representing a diverse range of clients, from institutional investors to private individuals. With numerous successful settlements under their belt, KSF advocates for investors facing losses from corporate misconduct. Their offices span key locations including New York, Delaware, California, and Louisiana, among others.

As this case progresses, it underscores the importance of awareness among investors, particularly concerning their rights in light of corporate disclosures. Investors are advised to pay close attention to updates and consult with legal experts when navigating potential claims against companies like ADMA Biologics that may have misled their investment community.

In conclusion, if you invested in ADMA Biologics during the specified period and suffered losses, make sure to act swiftly as the deadline for action approaches. The opportunity exists to recover losses, but prompt action will be necessary to secure a position in this class action lawsuit.